Base case results, primary analysis
| Strategy | 24-Month cost | 24-Month TLRs (%) | Cost difference | TLRs avoided | NNT to avoid 1 TLR in 24 months | Cost per TLR avoided | QALY gain (estimated) | ICER (£/QALY) (estimated) |
|---|---|---|---|---|---|---|---|---|
| PTA with bailout BMS→PTA with bailout BMS | £2863 | 36.2 | £0 | – | NA | NA | – | NA |
| BMS→PTA with bailout BMS | £2975 | 26.9 | £112 | 0.093 | 10.8 | £1204 | 0.005 | £20 719 |
| DCB→PTA with bailout BMS | £2906 | 17.6 | £43 | 0.187 | 5.4 | £231 | 0.011 | £3983 |
| DES→PTA with bailout BMS | £2907 | 19.4 | £44 | 0.168 | 6.0 | £264 | 0.010 | £4534 |
BMS, bare metal stent; DCB, drug-coated balloon; DES, drug-eluting stent; ICER, incremental cost-effectiveness ratio; NA, not available; NNT, number needed to treat; PTA, percutaneous transluminal balloon angioplasty; QALY, quality-adjusted life year; TLR, target lesion revascularisation.